胰腺癌的新辅助治疗

Neoadjuvant therapy for pancreatic cancer

胰腺癌恶性程度极高,单纯手术切除不能显著提高患者的远期生存率。新辅助治疗是指术前进行化疗或联合放化疗,旨在获得肿瘤降期、消灭亚临床转移灶,变不可切除肿瘤为可切除肿瘤,并提高胰腺癌的R0切除率,从而最终改善胰腺癌的疗效。目前对局部晚期和可能切除胰腺癌,新辅助治疗已逐渐成为主流的治疗方法;对可切除胰腺癌的新辅助治疗,已有部分高质量临床研究数据的支持,这方面会成为临床研究的热点。笔者相信,更多的临床研究数据将有助于个体化新辅助治疗方案的制订、精确疗效评估和预后判断,并最终改善胰腺癌患者的疗效。

Pancreatic cancer has a extremely high malignancy, and simple surgical resection can not significantly improve the long-term survival rate of patients. Neoadjuvant therapy is the preoperative chemotherapy or combined chemo-radiotherapy, which is used for downstaging tumors, eliminating subclinical metastases, transforming unresectable into resectable tumors, and improving the R0 resection rate of pancreatic cancer, thus ultimately improving the efficacy of pancreatic cancer. At present, neoadjuvant therapy has gradually become the mainstream treatment for locally advanced and borderline resectable pancreatic cancer. New adjuvant therapy for resectable pancreatic cancer has been supported by some high-quality clinical research data, which will become a hot topic in clinical research. The author believes that there will be more clinical research data to help individualized neoadjuvant treatment selection, accurate efficacy evaluation and prognosis judgement, and ultimately improve the efficacy of patients with pancreatic cancer.